National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Letermovir for the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).

NCPE Assessment Process Complete
Rapid review commissioned 12/03/2018
Rapid review completed 10/05/2018
Rapid Review outcome A Full pharmacoeconomic assessment is recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.